Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Gregory Y H Lip, Lars H Rasmussen, Bertil Olsson, Eva Jensen, Bengt Hamrén, Ulf Eriksson, Karin Wåhlander

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.
Originalspråkengelska
Sidor (från-till)1362-1373
TidskriftBritish Journal of Clinical Pharmacology
Volym80
Nummer6
DOI
StatusPublished - 2015

Ämnesklassifikation (UKÄ)

  • Farmakologi och toxikologi

Fingeravtryck

Utforska forskningsämnen för ”Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här